Postmenopausal breast cancer: is the short-term pain worth the long-term gain?
Pritchard
K I
KI
Division of Medical Oncology/Haematology, Toronto-Sunnybrook Regional Cancer Centre; University of Toronto, Ontario, Canada.
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D015337:Multicenter Studies as Topic; D017698:Postmenopause; D019057:Quality-Adjusted Life Years; D011960:Receptors, Estrogen / Q000032:analysis; D013629:Tamoxifen / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D013629:Tamoxifen